Skip to content

Surgical Stress and Colorectal Surgery

Evaluation of Surgical Stress and Immune Response After Minimally Invasive Colorectal Surgery (ESSIMIC)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02871960
Acronym
ESSIMIC
Enrollment
170
Registered
2016-08-18
Start date
2016-01-31
Completion date
2020-11-30
Last updated
2020-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Stress and Immune Function

Brief summary

The purpose of this study is to evaluate surgical stress and immune function after robotic versus laparoscopic colectomy.

Detailed description

The short-term advantages of minimally invasive colon resection have been well established in several randomized trials. A major factor in the development of morbidity is the surgical stress response with subsequent increased demand on the patient's reserves and immune competence. Although the advantage in term of stress response of laparoscopic surgery over open surgery has been widely reported, little is known about the role of robotic surgery. Robotic approaches have seen significant growth in the last 5 years. Taking advantage of three-dimensional visualization, improved articulation, and multiple operating arms provides theoretical advantages in colorectal cancer surgery. In an attempt to evaluate the surgical stress response and immune function after robotic colorectal surgery a comparative study has been designed. Two surgical procedures were evaluated: Robotic colorectal resection (Experimental group) and Laparoscopic colorectal resection (Control group).

Interventions

PROCEDURERobotic and Laparoscopic Colectomy

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Eligible patients will be those with a histologically confirmed malignancy planned for an elective, segmental, curative colectomy

Exclusion criteria

* Patients with a previous midline laparotomy, emergency surgery, or immune depressant disease or medication will be excluded from this study. Peri-operative or post-operative complications will be considered

Design outcomes

Primary

MeasureTime frame
interleukin 1change between time before surgery, 24 hours after surgery, 72 hours after surgery
interleukin 6change between time before surgery, 24 hours after surgery, 72 hours after surgery
Tumor necrosis factor alphachange between time before surgery, 24 hours after surgery, 72 hours after surgery
C-reactive proteinchange between time before surgery, 24 hours after surgery, 72 hours after surgery
fibrinogenchange between time before surgery, 24 hours after surgery, 72 hours after surgery
prolactinchange between time before surgery, 24 hours after surgery, 72 hours after surgery
cortisolchange between time before surgery, 24 hours after surgery, 72 hours after surgery
insulinchange between time before surgery, 24 hours after surgery, 72 hours after surgery
glucagonchange between time before surgery, 24 hours after surgery, 72 hours after surgery
Adrenocorticotropic hormonechange between time before surgery, 24 hours after surgery, 72 hours after surgery
Growth hormonechange between time before surgery, 24 hours after surgery, 72 hours after surgery
human leukocyte antigenchange between time before surgery, 24 hours after surgery, 72 hours after surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026